Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clearasil sale

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble solicits bids for anti-acne brand, retaining Goldman, Sachs to oversee a deal, the company announces Aug. 23. While Clearasil is profitable, the company says it is making "tough choices" on dedicating resources within the beauty care sector. Clearasil represents less than 2% of P&G's $7.39 bil. beauty care sales. The decision is part of P&G's brand review to refocus marketing spend on the firm's top 10 brands; Clearasil had been rumored to be on the selling block (1"The Rose Sheet" Aug. 7, p. 9). If P&G does not receive an "acceptable offer," it will retain the brand. Procter already has divested Prell shampoo and Coast soap

You may also be interested in...



Crest WhiteStrips Works In Two Weeks, Lasts Six Months - P&G

Procter & Gamble's Crest WhiteStrips, a do-it-yourself peroxide treatment for whitening teeth, is available through a Web site, whitestrips.com, and a toll-free number. While the strips have been sold at dentists' offices since July, wide distribution has not yet commenced.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel